Neumirna Therapeutics, a Danish biotechnology company specializing in RNA-based therapies for next-generation treatments of neurological disorders, has announced the first closing of its €20 million Series A financing round. The investment was co-led by new investors Angelini Ventures and Invivo Partners, alongside a significant contribution from Neumirna’s founding backer, Innovestor’s Life Science Fund, and other existing investors.
Founded to revolutionize treatment paradigms for neurological diseases, Neumirna is at the forefront of RNA-based innovation. The company leverages the potential of microRNAs—small regulatory RNAs that, while not encoding proteins, play a crucial role in gene expression.
“This emerging class of drugs promises to alter the course of complex and historically intractable diseases,” the company stated. “With its innovative platform, Neumirna is developing therapies targeting microRNAs to address conditions currently lacking effective treatments, such as drug-resistant epilepsy and Parkinson’s disease, offering new hope to patients suffering from these debilitating disorders. The vital role of microRNAs was internationally recognized in 2024 with the Nobel Prize in Physiology or Medicine awarded to scientists who discovered and characterized these powerful regulators of gene expression.”
Breakthrough Candidate Therapy: NMT.001
Neumirna’s lead therapeutic candidate, NMT.001, has shown promising results in preclinical studies for combating drug-resistant epilepsy. NMT.001 is an antisense oligonucleotide, a synthetic molecule designed to modulate the activity of a specific microRNA critical to gene expression regulation.
“In particular, NMT.001 was developed to interact with microRNA-134, a non-coding RNA sequence involved in regulating genes associated with drug-resistant epilepsy,” the company explained. “In various preclinical studies, NMT.001 has demonstrated a significant reduction in spontaneous or pharmacologically induced epileptic seizures, highlighting the molecule’s potential to substantially improve both the treatment and quality of life for patients.”
Advancing Innovative Therapies
Currently, no approved drugs utilize antisense technology to modulate microRNAs, making Neumirna’s platform highly innovative. The company is also exploring the application of this technology to Parkinson’s disease, broadening the therapeutic potential of its pipeline.
With the newly secured funding, Neumirna aims to strengthen its research and development efforts, enhance its platform, and advance NMT.001 through critical milestones toward clinical trials. This financing round represents a pivotal step for Neumirna in delivering transformative therapies to patients in need.
Leadership and Investor Support
“This significant funding validates the innovative potential of our microRNA-based platform and our lead development candidate, NMT.001,” said Janine Erler, CEO of Neumirna Therapeutics. “We are thrilled to have the support of leading international investors who share our vision to address unmet needs for patients with neurological disorders. This funding is essential for advancing NMT.001 into clinical trials and progressing the development of our drug candidate.”
Thomas Thestrup, Senior Principal at Angelini Ventures, emphasized the impact of Neumirna’s mission:
“As co-lead investors, we are proud to support Neumirna in leveraging RNA therapies to address complex neurological disorders. Neumirna is pioneering the development of microRNA-based drugs to tackle the root causes of conditions like epilepsy and Parkinson’s disease. With our strong focus on nervous system disorders and commitment to promoting innovative epilepsy treatments, we are excited to collaborate with Neumirna’s management on this journey to deliver groundbreaking solutions for patients worldwide.”
Luis Pareras, Managing Partner at Invivo Partners, added:
“Investing in Neumirna represents a unique opportunity to support a pioneering company in RNA technology for neurological disorders. As a neurosurgeon, I am deeply impressed by the innovative approach and preclinical results of NMT.001. Offering a novel solution for patients with refractory or drug-resistant epilepsy—a devastating condition—is incredibly encouraging.”
Strategic Governance
Both Pareras and Thestrup have been appointed to Neumirna’s Board of Directors, joining Milla Koistinaho of Innovestor’s Life Science Fund and Dr. Henrik Klitgaard, Neumirna’s scientific co-founder.
Towards Transformative Patient Outcomes
With this investment, Neumirna is poised to accelerate the development of RNA-based therapies, delivering innovative solutions for complex neurological conditions and improving the lives of patients globally.